Prins JM - Search Results

1

Effects of antiretroviral therapy on semen quality.

van Leeuwen E, Wit FW, Repping S, Eeftinck Schattenkerk JK, Reiss P, van der Veen F, Prins JM. van Leeuwen E, et al. Among authors: prins jm. AIDS. 2008 Mar 12;22(5):637-42. doi: 10.1097/QAD.0b013e3282f4de10. AIDS. 2008. PMID: 18317005

2

Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs.

van Rij RP, Visser JA, van Praag RM, Rientsma R, Prins JM, Lange JM, Schuitemaker H. van Rij RP, et al. Among authors: prins jm. J Virol. 2002 Mar;76(6):3054-8. doi: 10.1128/jvi.76.6.3054-3058.2002. J Virol. 2002. PMID: 11861873 Free PMC article.

3

Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy.

van Praag RM, Wit FW, Jurriaans S, de Wolf F, Prins JM, Lange JM. van Praag RM, et al. Among authors: prins jm. AIDS. 2002 Mar 29;16(5):719-25. doi: 10.1097/00002030-200203290-00007. AIDS. 2002. PMID: 11964528

4

Does highly active antiretroviral therapy induce sickle cell crises?

Lowe SH, Prins JM, van der Lelie J, Lange JM. Lowe SH, et al. Among authors: prins jm. AIDS. 2002 Jul 26;16(11):1572-4. doi: 10.1097/00002030-200207260-00024. AIDS. 2002. PMID: 12131205 No abstract available.

5

Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection.

Sankatsing SU, van Praag RM, van Rij RP, Rientsma R, Jurriaans S, Lange JM, Prins JM, Schuitemaker H. Sankatsing SU, et al. Among authors: prins jm. Antivir Ther. 2003 Apr;8(2):137-42. Antivir Ther. 2003. PMID: 12741626

6

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.

Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon F, Schreij G, Brinkman K, Richter C, Prins J, Aarnoutse R, Lange J; ATHENA Cohort Study Group. Burger D, et al. AIDS. 2003 May 23;17(8):1157-65. doi: 10.1097/00002030-200305230-00007. AIDS. 2003. PMID: 12819517 Clinical Trial.

7

Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients.

van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, Niesters HG, Osterhaus AD, Schutten M. van der Ende ME, et al. Among authors: prins jm. AIDS. 2003 Jul;17 Suppl 3:S55-61. doi: 10.1097/00002030-200317003-00008. AIDS. 2003. PMID: 14565610 Clinical Trial.

8

TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.

Sankatsing SU, Weverling GJ, Peeters M, van't Klooster G, Gruzdev B, Rakhmanova A, Danner SA, Jurriaans S, Prins JM, Lange JM. Sankatsing SU, et al. Among authors: prins jm. AIDS. 2003 Dec 5;17(18):2623-7. doi: 10.1097/00002030-200312050-00009. AIDS. 2003. PMID: 14685056 Clinical Trial.

9

Is the male genital tract really a sanctuary site for HIV? Arguments that it is not.

Lowe SH, Sankatsing SU, Repping S, van der Veen F, Reiss P, Lange JM, Prins JM. Lowe SH, et al. Among authors: prins jm. AIDS. 2004 Jul 2;18(10):1353-62. doi: 10.1097/01.aids.0000125979.64033.96. AIDS. 2004. PMID: 15199311 Review. No abstract available.

10

Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.

Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM. Nellen JF, et al. Among authors: prins jm. J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):943-50. doi: 10.1097/00126334-200408010-00008. J Acquir Immune Defic Syndr. 2004. PMID: 15220701

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

496 results

Search Page

Filters